Delirium primary prevention

Revision as of 05:00, 18 February 2014 by Pratik Bahekar (talk | contribs)
Jump to navigation Jump to search

Delirium Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Delirium from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case #1

Delirium On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Delirium

All Images
X-rays
Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Delirium

CDC on Delirium

Delirium in the news

Blogs on Delirium

Directions to Hospitals Treating Delirium

Risk calculators and risk factors for Delirium

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vishal Khurana, M.B.B.S., M.D. [2]; Pratik Bahekar, MBBS [3]

Overview

Primary Prevention

It is important to prevent delirium as delirium is itself neurotoxic. It is associated with global brain atrophy and white matter disruption. Various pharmacological interventions have shown promising results in prevention of delirium, which are as follows,

  • Post operative delirium,
    Haloperidol,
    Second-generation antipsychotics,
    Iliac fascia block,
    Gabapentin,
    Lower levels of intraoperative propofol sedation,
    A single dose of ketamine during anesthetic induction
  • Mechanically ventilated medical and surgical ICU patients,
    Continuous intravenous infusion of dexmedetomidine
  • Acutely ill general medical patients population,
    Melatonin[1]

Delirium possibly causes exhaustion leading to respiratory difficulties and a higher incidence of re-intubations. Haloperidol, if given prophylactically in lower doses, following benefits were observed,

  • Prophylactic treatment and early treatment seem to have a better prognosis than treatment of delirium.
  • Patients are less likely to remove their tubes or catheters
  • Patients with a higher risk of developing delirium benefited more.
  • ICU readmission rate was lower

Drawbacks for prophylactic treatment

  • Uneccesary treatment to patients who were not destined to develop delirium
  • Side effects of treatment, however QTc-time was only marginally prolonged and no one developed ventricular arrhythmias.

[2]

References

  1. "http://ajp.psychiatryonline.org/article.aspx?articleID=1795082". External link in |title= (help)
  2. "Haloperidol prophylaxis in critically ill patients... [Crit Care. 2013] - PubMed - NCBI".

Template:WH Template:WS